RET and non-small cell lung carcinoma: The ARROW clinical trial (Phase 1/2) reported that the response rate of pralsetinib in treatment-naive RET-altered non-small cell lung cancer patients was 73% (95% CI: 52%–88%), and the response rate in treated patients was 61% (95% CI: 50%–72%) (10).